These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 25978431)

  • 21. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-kappaB activation in anaplastic large cell lymphoma.
    Horie R; Watanabe M; Ishida T; Koiwa T; Aizawa S; Itoh K; Higashihara M; Kadin ME; Watanabe T
    Cancer Cell; 2004 Apr; 5(4):353-64. PubMed ID: 15093542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteome-wide identification of novel binding partners to the oncogenic fusion gene protein, NPM-ALK, using tandem affinity purification and mass spectrometry.
    Wu F; Wang P; Young LC; Lai R; Li L
    Am J Pathol; 2009 Feb; 174(2):361-70. PubMed ID: 19131589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
    Ceccon M; Merlo MEB; Mologni L; Poggio T; Varesio LM; Menotti M; Bombelli S; Rigolio R; Manazza AD; Di Giacomo F; Ambrogio C; Giudici G; Casati C; Mastini C; Compagno M; Turner SD; Gambacorti-Passerini C; Chiarle R; Voena C
    Oncogene; 2016 Jul; 35(29):3854-3865. PubMed ID: 26657151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.
    Murga-Zamalloa CA; Mendoza-Reinoso V; Sahasrabuddhe AA; Rolland D; Hwang SR; McDonnell SR; Sciallis AP; Wilcox RA; Bashur V; Elenitoba-Johnson K; Lim MS
    Oncogene; 2017 Apr; 36(15):2085-2094. PubMed ID: 27694894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK-Positive Anaplastic Large Cell Lymphoma.
    Ceccon M; Mologni L; Giudici G; Piazza R; Pirola A; Fontana D; Gambacorti-Passerini C
    Mol Cancer Res; 2015 Apr; 13(4):775-83. PubMed ID: 25421750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
    Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
    Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.
    Ambrogio C; Voena C; Manazza AD; Martinengo C; Costa C; Kirchhausen T; Hirsch E; Inghirami G; Chiarle R
    Cancer Res; 2008 Nov; 68(21):8899-907. PubMed ID: 18974134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
    Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
    J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity.
    Bai RY; Dieter P; Peschel C; Morris SW; Duyster J
    Mol Cell Biol; 1998 Dec; 18(12):6951-61. PubMed ID: 9819383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HuR-mediated control of C/EBPbeta mRNA stability and translation in ALK-positive anaplastic large cell lymphomas.
    Bergalet J; Fawal M; Lopez C; Desjobert C; Lamant L; Delsol G; Morello D; Espinos E
    Mol Cancer Res; 2011 Apr; 9(4):485-96. PubMed ID: 21343335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serine phosphorylation of NPM-ALK, which is dependent on the auto-activation of the kinase activation loop, contributes to its oncogenic potential.
    Wang P; Wu F; Zhang J; McMullen T; Young LC; Ingham RJ; Li L; Lai R
    Carcinogenesis; 2011 Feb; 32(2):146-53. PubMed ID: 21045017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
    Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
    Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways.
    Lim MS; Carlson ML; Crockett DK; Fillmore GC; Abbott DR; Elenitoba-Johnson OF; Tripp SR; Rassidakis GZ; Medeiros LJ; Szankasi P; Elenitoba-Johnson KS
    Blood; 2009 Aug; 114(8):1585-95. PubMed ID: 19531656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells.
    Ruchatz H; Coluccia AM; Stano P; Marchesi E; Gambacorti-Passerini C
    Exp Hematol; 2003 Apr; 31(4):309-15. PubMed ID: 12691918
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.
    Ambrogio C; Voena C; Manazza AD; Piva R; Riera L; Barberis L; Costa C; Tarone G; Defilippi P; Hirsch E; Boeri Erba E; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
    Blood; 2005 Dec; 106(12):3907-16. PubMed ID: 16105984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
    Han Y; Amin HM; Franko B; Frantz C; Shi X; Lai R
    Blood; 2006 Oct; 108(8):2796-803. PubMed ID: 16825495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
    Hsu FY; Johnston PB; Burke KA; Zhao Y
    Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis.
    Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M
    Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EBP2, a novel NPM-ALK-interacting protein in the nucleolus, contributes to the proliferation of ALCL cells by regulating tumor suppressor p53.
    Uchihara Y; Tago K; Tamura H; Funakoshi-Tago M
    Mol Oncol; 2021 Jan; 15(1):167-194. PubMed ID: 33040459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lobatin B inhibits NPM/ALK and NF-κB attenuating anaplastic-large-cell-lymphomagenesis and lymphendothelial tumour intravasation.
    Kiss I; Unger C; Huu CN; Atanasov AG; Kramer N; Chatruphonprasert W; Brenner S; McKinnon R; Peschel A; Vasas A; Lajter I; Kain R; Saiko P; Szekeres T; Kenner L; Hassler MR; Diaz R; Frisch R; Dirsch VM; Jäger W; de Martin R; Bochkov VN; Passreiter CM; Peter-Vörösmarty B; Mader RM; Grusch M; Dolznig H; Kopp B; Zupko I; Hohmann J; Krupitza G
    Cancer Lett; 2015 Jan; 356(2 Pt B):994-1006. PubMed ID: 25444930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.